Skip Nav Destination
Issues
1 April 2008
-
Cover Image
Cover Image
(A) Tumor spheroids isolated from eGFP mice exposed to CM-DiI-labeled liposomes or PBS show eGFP-expressing stromal cells (green fluorescence), cells that have endocytosed CM-DiI-labeled liposomes (red fluorescence), and a subpopulation of host stromal cells that uptake liposomes (yellow or orange fluorescence, arrows). (B) Tumor spheroids from C57Bl/6 mice exposed to CM-DiI-labeled liposomes or PBS and labeled for expression of the macrophage marker CD68 (green fluorescence) show colocalization of CM-DiI andCD68 (yellow or orange fluorescence, arrows). (C) Spheroids exposed as described in (B) and labeled for the dendritic cell marker CD11c (green fluorescence, arrows) show no colocalization. D. CM-DiI-labeled or unlabeled macrophages were treated with CLIP or PLIP and the conditioned medium was transferred to cultures of mesothelioma cells. Cells incubated in conditioned medium from CM-DiI-labeled CLIP-treated macrophages (left, arrows); cells incubated in conditioned medium from CM-DiI-labeled, PLIP-treated macrophages (middle) or unlabeled, CLIP-treated macrophages (right). All cells were counterstained with DAPI (blue nuclear fluorescence). For details, see Miselis et al. in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Spotlight on Clinical Response
Review
Research Articles: Therapeutics, Targets, and Development
Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor-κB, p53, bax, and p27 levels
Catherine A. Tucker; Anita I. Kapanen; Ghania Chikh; Brad G. Hoffman; Alastair H. Kyle; Ian M. Wilson; Dana Masin; Randy D. Gascoyne; Marcel Bally; Richard J. Klasa
MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo
Marielle Fournel; Claire Bonfils; Yu Hou; Pu Theresa Yan; Marie-Claude Trachy-Bourget; Ann Kalita; Jianhong Liu; Ai-Hua Lu; Nancy Z. Zhou; Marie-France Robert; Jeffrey Gillespie; James J. Wang; Hélène Ste-Croix; Jubrail Rahil; Sylvain Lefebvre; Oscar Moradei; Daniel Delorme; A. Robert MacLeod; Jeffrey M. Besterman; Zuomei Li
Sensitizing estrogen receptor–negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1/Akt signaling inhibitor
Shu-Chuan Weng; Yoko Kashida; Samuel K. Kulp; Dasheng Wang; Robert W. Brueggemeier; Charles L. Shapiro; Ching-Shih Chen
Pharmacologic properties of AG-012986, a pan-cyclin-dependent kinase inhibitor with antitumor efficacy
Cathy Zhang; Karen Lundgren; Zhengming Yan; Maria E. Arango; Sharon Price; Andrea Huber; Joseph Higgins; Gabriel Troche; Judith Skaptason; Tatiana Koudriakova; Jim Nonomiya; Michelle Yang; Patrick O'Connor; Steve Bender; Gerrit Los; Cristina Lewis; Bart Jessen
Characterization of structurally distinct, isoform-selective phosphoinositide 3′-kinase inhibitors in combination with radiation in the treatment of glioblastoma
Jack S. Chen; Linda J. Zhou; Michal Entin-Meer; Xiaodong Yang; Mila Donker; Zachary A. Knight; William Weiss; Kevan M. Shokat; Daphne Haas-Kogan; David Stokoe
Antitumor activity of fibroblast growth factor receptor 3–specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis
Jorge L. Martínez-Torrecuadrada; Lawrence H. Cheung; Paula López-Serra; Rodrigo Barderas; Marta Cañamero; Sergio Ferreiro; Michael G. Rosenblum; J. Ignacio Casal
Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells
Maria Serova; Aïda Ghoul; Karim A. Benhadji; Sandrine Faivre; Christophe Le Tourneau; Esteban Cvitkovic; Francois Lokiec; Janet Lord; Steven M. Ogbourne; Fabien Calvo; Eric Raymond
A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras
Yanan Yang; Marie Wislez; Nobukazu Fujimoto; Ludmila Prudkin; Julie G. Izzo; Futoshi Uno; Lin Ji; Amy E. Hanna; Robert R. Langley; Diane Liu; Faye M. Johnson; Ignacio Wistuba; Jonathan M. Kurie
Correction
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.